SCHEMBL12096850

SCHEMBL12096850

CC(C)c1ccc(S(=O)(=O)n2c(OCc3ccc(C(=O)O)cc3)cc3cc(Cl)ccc32)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 2/20 0.49
▸ RXRB P28702 2/20 0.49
▸ ACLY P53396 4/20 0.48
▸ MRGPRX4 Q96LA9 3/20 0.46
▸ PSEN1 P49768 1/20 0.45
▸ PSEN2 P49810 1/20 0.45
▸ APH1B Q8WW43 1/20 0.45
▸ NCSTN Q92542 1/20 0.45
▸ APH1A Q96BI3 1/20 0.45
▸ PSENEN Q9NZ42 1/20 0.45
▸ PPARG P37231 6/20 0.45
▸ PPARA Q07869 4/20 0.45
▸ PPARD Q03181 3/20 0.45
▸ BCL2 P10415 1/20 0.43
▸ BID P55957 1/20 0.43
▸ MCL1 Q07820 1/20 0.43
▸ PHGDH O43175 1/20 0.43
▸ NR4A2 P43354 1/20 0.41
▸ RXRG P48443 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12096941 0.83 PPARG (0.52) ACLYPPARGPPARAPPARDPHGDH
SCHEMBL12096852 0.80 ACLY (0.53) ACLYPSEN1PSEN2APH1BNCSTN
SCHEMBL12096680 0.79 ACLY (0.52) ACLYPPARGPPARAPPARDPHGDH
SCHEMBL12096736 0.76 ACLY (0.49) ACLYPPARGPPARAPPARDPHGDH
SCHEMBL12096711 0.76 PPARG (0.52) ACLYMRGPRX4PSEN1PSEN2APH1B
SCHEMBL3529263 0.75 PPARG (0.78) PPARGPPARAPPARD
SCHEMBL12096814 0.75 PPARG (0.54) ACLYPPARGPPARAPPARD
SCHEMBL12096731 0.75 PPARG (0.52) ACLYPPARGPPARAPPARD
SCHEMBL12096655 0.74 PPARG (0.57) ACLYPPARGPPARAPPARD
SCHEMBL12096688 0.74 PPARG (0.55) ACLYPPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232070-A1 Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease LABORATOIRES FOURNIER SA (FR) 2012-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232070-A1 Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease NCOR1, NR0B1, MTNR1A RXRA 205/4885RXRB 192/4885ACLY 3538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback